NCT04919538 Longitudinal Study for Relapsing Polychondritis
| NCT ID | NCT04919538 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Relapsing Polychondritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-02-26 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2021-02-26 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system, skin and inner ear. The purpose of this study is to study the pathogenesis of RP.
Eligibility Criteria
Inclusion Criteria: * 1\. Any subject considered to have a diagnosis of relapsing polychondritis according to the investigator. Exclusion Criteria: * 1\. Inability to provide consent, or in the case of minors, assent.
Contact & Investigator
Peter Merkel, MD, MPH
STUDY DIRECTOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT04919538 clinical trial?
This trial is open to participants of all sexes, studying Relapsing Polychondritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04919538 currently recruiting?
Yes, NCT04919538 is actively recruiting participants. Contact the research team at cmcalear@upenn.edu for enrollment information.
Where is the NCT04919538 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT04919538 clinical trial?
NCT04919538 is sponsored by University of Pennsylvania. The principal investigator is Peter Merkel, MD, MPH at University of Pennsylvania. The trial plans to enroll 100 participants.